Phase II trial of carboplatin and pemetrexed plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Jan 2018 Planned End Date changed from 1 May 2017 to 1 May 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 May 2016 to 1 May 2019.
- 12 Aug 2015 Planned End Date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov record